Sagimet Biosciences Inc. (SGMT) intrinsic value & 10-year financials
Sagimet Biosciences Inc. (SGMT) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $8.02
- Market cap
- $259.4M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -29.1%
- Free cash flow (FY2025)
- —
SGMT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$51.0M | -$1.58 | — | — | -74.5% |
| FY2024 | — | -$45.6M | -$1.45 | — | — | — |
| FY2023 | $2.0M | -$27.9M | -$0.89 | — | -1537.0% | — |
| FY2022 | — | -$30.5M | -$0.97 | — | — | 16.3% |
| FY2021 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Sagimet Biosciences Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Sagimet Biosciences Inc. has historically struggled to out-earn its cost of capital, averaging just -29.1% ROIC.
Sagimet Biosciences Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Sagimet Biosciences Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.